Pierre Fabre restructures ailing pharma business
This article was originally published in Scrip
Just over a year after the death of its eponymous founder, French health and beauty firm Pierre Fabre has announced restructuring plans that include radical action and 551 job losses in its ailing pharma business, most of which will be in France. The company intends to focus its pharma business on three key therapy areas: oncology, neuropsychiatry and dermatology, with a fourth business unit dedicated to consumer healthcare.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.